These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 36802876)

  • 1. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
    Milling TJ; Middeldorp S; Xu L; Koch B; Demchuk A; Eikelboom JW; Verhamme P; Cohen AT; Beyer-Westendorf J; Gibson CM; Lopez-Sendon J; Crowther M; Shoamanesh A; Coppens M; Schmidt J; Albaladejo P; Connolly SJ;
    Circulation; 2023 Mar; 147(13):1026-1038. PubMed ID: 36802876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity: Prespecified Subgroup Analysis of the ANNEXA-4 Study in Japan.
    Toyoda K; Arakawa S; Ezura M; Kobayashi R; Tanaka Y; Hasegawa S; Yamashiro S; Komatsu Y; Terasawa Y; Masuno T; Kobayashi H; Oikawa S; Yasaka M
    J Atheroscler Thromb; 2024 Mar; 31(3):201-213. PubMed ID: 37635060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
    Connolly SJ; Milling TJ; Eikelboom JW; Gibson CM; Curnutte JT; Gold A; Bronson MD; Lu G; Conley PB; Verhamme P; Schmidt J; Middeldorp S; Cohen AT; Beyer-Westendorf J; Albaladejo P; Lopez-Sendon J; Goodman S; Leeds J; Wiens BL; Siegal DM; Zotova E; Meeks B; Nakamya J; Lim WT; Crowther M;
    N Engl J Med; 2016 Sep; 375(12):1131-41. PubMed ID: 27573206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy.
    Demchuk AM; Yue P; Zotova E; Nakamya J; Xu L; Milling TJ; Ohara T; Goldstein JN; Middeldorp S; Verhamme P; Lopez-Sendon JL; Conley PB; Curnutte JT; Eikelboom JW; Crowther M; Connolly SJ;
    Stroke; 2021 Jun; 52(6):2096-2105. PubMed ID: 33966491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.
    Connolly SJ; Crowther M; Eikelboom JW; Gibson CM; Curnutte JT; Lawrence JH; Yue P; Bronson MD; Lu G; Conley PB; Verhamme P; Schmidt J; Middeldorp S; Cohen AT; Beyer-Westendorf J; Albaladejo P; Lopez-Sendon J; Demchuk AM; Pallin DJ; Concha M; Goodman S; Leeds J; Souza S; Siegal DM; Zotova E; Meeks B; Ahmad S; Nakamya J; Milling TJ;
    N Engl J Med; 2019 Apr; 380(14):1326-1335. PubMed ID: 30730782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
    Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI
    Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban.
    Benz AP; Xu L; Eikelboom JW; Middeldorp S; Milling TJ; Crowther M; Yue P; Conley P; Lu G; Connolly SJ;
    Thromb Haemost; 2022 Jun; 122(6):998-1005. PubMed ID: 34996121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Andexanet Alfa (Andexxa) Formulary Review.
    Beik N; Reddy P; Sylvester KW; Connell NT; Giugliano RP; Piazza G; Connors JM
    Crit Pathw Cardiol; 2019 Jun; 18(2):66-71. PubMed ID: 31094731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care.
    Huttner HB; Gerner ST; Kuramatsu JB; Connolly SJ; Beyer-Westendorf J; Demchuk AM; Middeldorp S; Zotova E; Altevers J; Andersohn F; Christoph MJ; Yue P; Stross L; Schwab S
    Stroke; 2022 Feb; 53(2):532-543. PubMed ID: 34645283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers.
    Lu G; Conley PB; Leeds JM; Karbarz MJ; Levy GG; Mathur VS; Castillo J; Crowther M; Curnutte JT
    Blood Adv; 2020 Feb; 4(4):728-739. PubMed ID: 32092140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal.
    Maragkos GA; Nelton EB; Richter S; Stippler M
    World Neurosurg; 2020 Oct; 142():e95-e100. PubMed ID: 32561488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures.
    Bradshaw PG; Keegan SP; Droege ME; Dykes NJH; Ernst NE; Foertsch MJ; Makley AT; Mueller EW; Philpott CD; Srinivasan V; Winter JB; Goodman MD; Droege CA
    Pharmacotherapy; 2022 Oct; 42(10):780-791. PubMed ID: 36073083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Andexanet alfa (ONDEXXYA
    Yajima T; Higashimori M; Takata C; Sasabe T
    Nihon Yakurigaku Zasshi; 2023; 158(1):89-100. PubMed ID: 36596498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
    Siegal DM; Curnutte JT; Connolly SJ; Lu G; Conley PB; Wiens BL; Mathur VS; Castillo J; Bronson MD; Leeds JM; Mar FA; Gold A; Crowther MA
    N Engl J Med; 2015 Dec; 373(25):2413-24. PubMed ID: 26559317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa.
    Nederpelt CJ; Naar L; Sylvester KW; Barra ME; Roberts RJ; Velmahos GC; Kaafarani HMA; Rosenthal MG; King DR
    J Thromb Haemost; 2020 Oct; 18(10):2532-2541. PubMed ID: 32738161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world utilization of andexanet alfa.
    Brown CS; Scott RA; Sridharan M; Rabinstein AA
    Am J Emerg Med; 2020 Apr; 38(4):810-814. PubMed ID: 31870672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage.
    Giovino A; Shomo E; Busey KV; Case D; Brockhurst A; Concha M
    Clin Neurol Neurosurg; 2020 Aug; 195():106070. PubMed ID: 32679541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of andexanet alpha in the Polish setting: An interdisciplinary protocol. Expert consensus statement of the Polish Cardiac Society.
    Kazimierczyk E; Dąbrowska M; Gierlotka M; Kapica-Topczewska K; Karaszewski B; Kobayashi A; Krasiński Z; Kubica J; Kułakowska A; Kurek K; Ładny R; Pleban E; Rejdak K; Rydzewska G; Słowik A; Szopiński P; Woźniak A; Tycińska A
    Kardiol Pol; 2024; 82(1):123-139. PubMed ID: 38230495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of an andexanet alfa administration protocol guided by drug-specific quantitative anti-Xa assays.
    Lanham HT; Viriyakitja W; Vestal M; Welsby I; Kram B
    J Thromb Thrombolysis; 2024 Feb; 57(2):285-292. PubMed ID: 37932587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of andexanet alfa and prothrombin complex concentrate in reversing anticoagulation by rivaroxaban ex vivo.
    Rayatdoost F; Deventer K; Rossaint R; Schöchl H; Grottke O
    Br J Anaesth; 2024 Feb; 132(2):251-259. PubMed ID: 38030550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.